Ovid Therapeutics Inc.
OVID· Nasdaq
Released Nov 8, 2022, before the open
10-Q filed Nov 8, 2022, 39 days after period end · 0001628280-22-028772
| Metric | Q3 2022 | Q3 2021 | Q3 2020 | Q3 2019 |
|---|---|---|---|---|
| Revenue | $11.10K | $0.00 | $6.91M | — |
| Net Income | -$11.97M | -$11.38M | -$16.42M | -$16.63M |
| EPS Diluted |
Ovid Therapeutics Inc. · CIK 1636651 · Engraved from SEC EDGAR
| -$0.17 |
| -$0.17 |
| -$0.28 |
| -$0.43 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.